Article
Oncology
Lucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, Riccardo Ponzone, Antonio Durando, Laura Amaducci, Enrico Campadelli, Francesco Cognetti, Antonio Frassoldati, Andrea Michelotti, Silvia Mura, Ylenia Urracci, Giovanni Sanna, Stefania Gori, Sabino De Placido, Ornella Garrone, Alessandra Fabi, Carla Barone, Stefano Tamberi, Claudia Bighin, Fabio Puglisi, Gabriella Moretti, Grazia Arpino, Alberto Ballestrero, Francesca Poggio, Matteo Lambertini, Filippo Montemurro, Paolo Bruzzi
Summary: The study showed that extending letrozole treatment to 5 years in postmenopausal patients with breast cancer who had received 2-3 years of tamoxifen resulted in a significant improvement in disease-free survival compared to the standard 2-3 years of letrozole treatment.
Article
Oncology
Masakazu Toi, Shigeru Imoto, Takanori Ishida, Yoshinori Ito, Hiroji Iwata, Norikazu Masuda, Hirofumi Mukai, Shigehira Saji, Akira Shimizu, Takafumi Ikeda, Hironori Haga, Toshiaki Saeki, Kenjiro Aogi, Tomoharu Sugie, Takayuki Ueno, Takayuki Kinoshita, Yuichiro Kai, Masahiro Kitada, Yasuyuki Sato, Kenjiro Jimbo, Nobuaki Sato, Hiroshi Ishiguro, Masahiro Takada, Yasuo Ohashi, Shinji Ohno
Summary: This study is a multicentre, phase 3 trial that aimed to investigate the efficacy of oral fluoropyrimidines S-1 in combination with endocrine therapy for ER-positive, HER2-negative primary breast cancer. The results showed a significant reduction in invasive disease-free survival events in the S-1 plus endocrine therapy group compared to the endocrine therapy alone group at the interim analysis, indicating that S-1 in combination with endocrine therapy could be a potential treatment option.
Article
Oncology
Takuji Iwase, Shigehira Saji, Kotaro Iijima, Kenji Higaki, Shoichiro Ohtani, Yasuyuki Sato, Yasuo Hozumi, Yoshie Hasegawa, Yasuhiro Yanagita, Hiroyuki Takei, Maki Tanaka, Hideji Masuoka, Masahiko Tanabe, Chiyomi Egawa, Yoshifumi Komoike, Toshitaka Nakamura, Hiroshi Ohtsu, Hirofumi Mukai
Summary: This study investigated the effects of extending the treatment with an aromatase inhibitor for 10 years on disease-free survival in postmenopausal hormone receptor-positive breast cancer patients. The results showed that extending the treatment with an aromatase inhibitor for an additional 5 years improved disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Shinji Ohno, Shigehira Saji, Norikazu Masuda, Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosumi, Akihiko Shimomura, Nobuaki Sato, Shintaro Takao, Shozo Ohsumi, Yutaka Tokuda, Hideo Inaji, Toru Watanabe, Yasuo Ohashi
Summary: The study found that there were no significant differences in RFS and OS between patients with luminal-type breast cancer treated with CMF and UFT. However, in patients with the HR-/HER2+ subtype, RFS was significantly longer in the UFT treatment group compared to the CMF group. High levels of tumor-infiltrating lymphocytes were associated with better overall survival.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Sheng-Kai Liang, Chang-Wei Wu, Ching- Chang, Li-Ta Keng, Meng-Rui Lee, Jann-Yuan Wang, Jen-Chung Ko, Wei-Yu Liao, Kuan-Yu Chen, Chao-Chi Ho, Jin-Yuan Shih, Chong-Jen Yu
Summary: This study compared the effectiveness of adjuvant oral UFT and intravenous chemotherapy in early-stage NSCLC patients after surgery and found that both treatments had comparable clinical outcomes.
Article
Oncology
Kathy Pan, Aaron K. Aragaki, Marian L. Neuhouser, Michael S. Simon, Juhua Luo, Bette Caan, Linda Snetselaar, Joanne E. Mortimer, JoAnn E. Manson, Candyce Kroenke, Dorothy Lane, Kerryn Reding, Thomas E. Rohan, Rowan T. Chlebowski
Summary: The study found that postmenopausal women with 3-4 metabolic syndrome components were at higher risk of death from breast cancer. However, those who were randomized to a low-fat dietary intervention were more likely to have a reduction in this risk.
BRITISH JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Timothy J. Whelan, Sally Smith, Sameer Parpia, Anthony W. Fyles, Anita Bane, Fei-Fei Liu, Eileen Rakovitch, Lynn Chang, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Valerie Theberge, Anna Marie Mulligan, Zuzana Kos, Mohamed A. Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory Pond, James R. Wright, Torsten O. Nielsen, Mark N. Levine
Summary: Among women with T1N0 grade 1 or 2 luminal A breast cancer who had undergone breast-conserving surgery and received endocrine therapy, the incidence of local recurrence at 5 years was low without radiotherapy.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Sara A. Hurvitz, Aditya Bardia, Vanesa Quiroga, Yeon Hee Park, Isabel Blancas, Jose Luis Alonso-Romero, Aleksandr Vasiliev, Hryhoriy Adamchuk, Marcelo Salgado, Denise A. Yardley, Oleksandr Berzoy, Pilar Zamora-Aunon, David Chan, Gonzalo Spera, Cloris Xue, Erika Ferreira, Tanja Badovinac Crnjevic, Pablo Diego Perez-Moreno, Vanesa Lopez-Valverde, Jutta Steinseifer, Tharu M. Fernando, Heather M. Moore, coopERA Breast Cancer study grp
Summary: This study compared the efficacy of the SERD giredestrant with anastrozole in treating ER-positive, HER2-negative early breast cancer, demonstrating that giredestrant has a stronger anti-proliferative effect and is well-tolerated. The results support further investigation in ongoing trials.
Article
Oncology
Eve Rodler, Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders, Lori Goldstein, Debu Tripathy, Ursa A. Brown-Glaberman, Thu-Tam Huynh, Christopher S. Szyarto, Andrew K. Godwin, Harsh B. Pathak, Elizabeth M. Swisher, Marc R. Radke, Kirsten M. Timms, Danika L. Lew, Jieling Miao, Lajos Pusztai, Daniel F. Hayes, Gabriel N. Hortobagyi
Summary: PARP inhibitors are effective in germline BRCA1/2-mutated metastatic breast cancer. This study demonstrates that adding veliparib to cisplatin improves progression-free survival in patients with BRCA-like metastatic triple-negative breast cancer.
Article
Medicine, General & Internal
Ian H. H. Kunkler, Linda J. J. Williams, Wilma J. L. Jack, David A. A. Cameron, J. Michael Dixon
Summary: This study suggests that omission of radiotherapy in older women with low-risk, hormone receptor-positive early breast cancer may increase the risk of local recurrence, but has no detrimental effect on distant recurrence and overall survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Taishi Hata, Kiyotaka Hagihara, Anna Tsutsui, Hiroki Akamatsu, Masayuki Ohue, Tatsushi Shingai, Mitsuyoshi Tei, Masakazu Ikenaga, Ho Min Kim, Hideki Osawa, Hiroyoshi Takemoto, Ken Konishi, Mamoru Uemura, Chu Matsuda, Tsunekazu Mizushima, Kohei Murata, Yuko Ohno, Yuichiro Doki, Hidetoshi Eguchi
Summary: The twice-daily regimen of UFT/LV showed noninferiority and no increase in adverse events compared to the conventional three-times-daily regimen. This provides more treatment options, especially for elderly or frail patients, highlighting the importance of personalized medicine.
Article
Oncology
Neda Rajabi, Fateme Mohammadnejad, Mohammad Amin Doustvandi, Mahdi Abdoli Shadbad, Mohammad Amini, Habib Tajalli, Ahad Mokhtarzadeh, Elham Baghbani, Nicola Silvestris, Behzad Baradaran
Summary: Photodynamic therapy (PDT) combined with tamoxifen (TA) has shown promising anti-cancer effects on MDA-MB-231 cells. The combination treatment increased cytotoxicity, induced apoptosis, inhibited migration, and suppressed clonogenicity. Furthermore, the synergy between ZnPc-PDT and TA enhanced the cytotoxicity and modulated gene expression.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
(2023)
Article
Medicine, General & Internal
Amy H. Farkas, Ann B. Nattinger
Summary: Breast cancer is the most common cancer among U.S. women, with its incidence increasing with age. Various factors like endogenous estrogen exposure, benign breast disease, breast density, and family history can indicate increased risk for breast cancer. Early detection through screening mammography helps reduce breast cancer mortality, but the benefits vary depending on age. Evaluating a patient's individual risk can guide decisions on breast cancer screening. All women benefit from healthy behaviors that can lower the risk. Women at higher risk may benefit from risk-reducing medications. The use of screening measures, especially among uninsured women, remains suboptimal.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Medicine, General & Internal
Michael Gnant, Florian Fitzal, Gabriel Rinnerthaler, Guenther G. Steger, Sigrun Greil-Ressler, Marija Balic, Dietmar Heck, Raimund Jakesz, Josef Thaler, Daniel Egle, Diether Manfreda, Vesna Bjelic-Radisic, Ursula Wieder, Christian F. Singer, Elisabeth Melbinger-Zeinitzer, Ferdinand Haslbauer, Paul Sevelda, Harald Trapl, Viktor Wette, Kerstin Wimmer, Simon P. Gampenrieder, Rupert Bartsch, Stephanie Kacerovsky-Strobl, Christoph Suppan, Christine Brunner, Christine Deutschmann, Lidija Soelkner, Christian Fesl, Richard Greil
Summary: This study showed that extending hormone therapy by 5 years in postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Marike Gabrielson, Mattias Hammarstrom, Magnus Baecklund, Jenny Bergqvist, Kristina Lang, Ann H. Rosendahl, Signe Borgquist, Roxanna Hellgren, Kamila Czene, Per Hall
Summary: This study found that different doses of tamoxifen can reduce the recurrence of breast cancer and have an influence on the breast tissue composition and histological markers. High-dose tamoxifen decreased the epithelial area in postmenopausal women without measurable density decrease.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Surgery
Taijiro Sueda, Shinya Takahashi
Article
Oncology
Kazuhiro Toyota, Yoshiaki Murakami, Naru Kondo, Kenichiro Uemura, Naoya Nakagawa, Shinya Takahashi, Taijiro Sueda
ANNALS OF SURGICAL ONCOLOGY
(2018)
Article
Cardiac & Cardiovascular Systems
Shinya Takahashi, Kei Nakagawa, Mayumi Tomiyasu, Ayumu Nakashima, Keijiro Katayama, Takeshi Imura, Bagus Herlambang, Tomoe Okubo, Koji Arihiro, Yumi Kawahara, Louis Yuge, Taijiro Sueda
ANNALS OF THORACIC SURGERY
(2018)
Letter
Pediatrics
Alexander J. Towbin, Rebecka L. Meyers, Helen Woodley, Osamu Miyazaki, Christopher B. Weldon, Bruce Morland, Eiso Hiyama, Piotr Czauderna, Derek J. Roebuck, Greg M. Tiao
PEDIATRIC RADIOLOGY
(2018)
Article
Chemistry, Analytical
Ahmed Ali, Yasmine Abouleila, Yoshihiro Shimizu, Eiso Hiyama, Tomonobu M. Watanabe, Toshio Yanagida, Arno Germond
ANALYTICAL CHEMISTRY
(2019)
Article
Oncology
Yasmine Abouleila, Kaoru Onidani, Ahmed Ali, Hirokazu Shoji, Takayuki Kawai, Chwee Teck Lim, Vipin Kumar, Shinobu Okaya, Ken Kato, Eiso Hiyama, Toshio Yanagida, Tsutomu Masujima, Yoshihiro Shimizu, Kazufumi Honda
Review
Pediatrics
Tomoro Hishiki, Shohei Honda, Yuichi Takama, Yukihiro Inomata, Hideaki Okajima, Ken Hoshino, Tatsuya Suzuki, Ryota Souzaki, Motoshi Wada, Mureo Kasahara, Koichi Mizuta, Takaharu Oue, Akiko Yokoi, Takuro Kazama, Shugo Komatsu, Isamu Saeki, Osamu Miyazaki, Tetsuya Takimoto, Kohmei Ida, Kenichiro Watanabe, Eiso Hiyama
Summary: The study involved using a real-time central surgical reviewing system to facilitate early referral of liver transplantation candidates, leading to prompt surgical decisions and procedures.
Article
Oncology
Takahiro Fukazawa, Keiji Tanimoto, Emi Yamaoka, Masato Kojima, Masami Kanawa, Nobuyuki Hirohashi, Eiso Hiyama
Summary: Hepatoblastoma (HBL) is a rare liver malignancy that occurs mainly in early childhood. Although treatment regimens have improved the prognosis, there are still refractory cases and the current treatment often leads to severe side effects. This study demonstrates that ADAM32, a protein involved in various cancer types, is highly expressed in HBL and is associated with poor prognosis. ADAM32 plays a role in cancer cell proliferation, stemness, migration, invasion, and chemotherapy resistance. This suggests that ADAM32 could be a promising target for therapy and provides insights into the molecular mechanisms of HBL carcinogenesis.
Article
Cell Biology
Yoko Hiyama, Emi Yamaoka, Takahiro Fukazawa, Masato Kojima, Yusuke Sotomaru, Eiso Hiyama
Summary: In this study, we investigated the association between the expression of DHRS3, NROB1, and CYP26A1 genes and the suppression of neuroblastoma cell growth. The overexpression of these genes led to a reduction in cell growth and induced morphological senescence, mainly through pathways related to cellular senescence and cell adhesion. DHRS3 and NROB1 also arrested the cell cycle and induced differentiation and senescence. These findings suggest that the induction of these genes could be a potential therapeutic strategy for suppressing high-risk neuroblastoma growth.
Article
Oncology
Angela D. Trobaugh-Lotrario, Rudolf Maibach, Daniel C. Aronson, Arun Rangaswami, Beate Haeberle, Allison F. O'Neill, Irene Schmid, Marc Ansari, Tomoro Hishiki, Sarangarajan Ranganathan, Rita Alaggio, Ronald R. de Krijger, Yukichi Tanaka, Soo-Jin Cho, Christian Vokuhl, Rebecca Maxwell, Mark Krailo, Eiso Hiyama, Piotr Czauderna, Milton Finegold, James H. Feusner, Marcio H. Malogolowkin, Rebecka L. Meyers, Dolores Lopez-Terrada
Summary: Hepatoblastoma is the most common malignant liver tumor in children, and small cell undifferentiated histology and low alpha-fetoprotein levels have been associated with poor prognosis. It is important to differentiate rhabdoid tumors from hepatoblastoma with small cell undifferentiated component or low alpha-fetoprotein levels, as the treatment differs significantly. When rhabdoid tumors are correctly diagnosed, neither the presence of small cell undifferentiated component nor low alpha-fetoprotein levels are associated with poor prognosis.
Article
Biology
Sungmin Yang, Kyungsik Ha, Woojeung Song, Masashi Fujita, Kirsten Kuebler, Paz Polak, Eiso Hiyama, Hidewaki Nakagawa, Hong-Gee Kim, Hwajin Lee
Summary: We have developed COOBoostR, a computational method that can predict the tissue or cell of origin for various types of cancer. COOBoostR uses regional somatic mutation density information and chromatin mark features in an extreme gradient boosting-based machine-learning algorithm. By ranking chromatin marks from different tissue and cell types, COOBoostR can determine the most likely tissue or cell of origin based on the somatic mutation density landscape of a sample.
Article
Pediatrics
Masumi Kawashima, Yuka Ueda, Sho Kurihara, Noriyuki Shiroma, Eiso Hiyama
JOURNAL OF PEDIATRIC SURGERY CASE REPORTS
(2019)
Meeting Abstract
Oncology
Eiso Hiyama
Meeting Abstract
Oncology
Genta Nagae, Shogo Yamamoto, Kenji Tatsuno, Claire Renard-Guillet, Takayoshi Umeda, Shuichi Tsutsumi, Masashi Fujita, Hidewaki Nakagawa, Eiso Hiyama, Hiroyuki Aburatani
Meeting Abstract
Oncology
Sunao Fujiyoshi, Shohei Honda, Masashi Minato, Hiromu Suzuki, Eso Hiyama, Akinobu Taketomi